Open Targets is based on the stunning Wellcome Genome Campus, home to some of the world's foremost institutes and organisations in genomics and computational biology. We work in dynamic teams at the interface of academic and pharma industry science on a crucial problem, how to be more successful in making drugs. Working with us, you will be exposed to new technologies and a dynamic set of scientists dedicated to translational research.
Our posts are usually in either one of our academic partners, The Wellcome Sanger Institute or EMBL-EBI and have terms and conditions associated with the employer.
Important note: applications may be reviewed on an ongoing basis and the advertised post(s) may be filled before the stated deadline.
A Senior Bioinformatician role is available within Open Targets under the leadership of Dr. Maya Ghoussaini for a 2 year fixed term contract.
This is an exciting opportunity for you to participate in the enhancement of Open Targets Genetics (genetics.opentargets.org) through the development of new functionality and features using state of the art statistical genetics analysis. You will actively engage in the integration of data from several genetic analyses including rare variant association analyses, burden tests in large-scale datasets such as the UK Biobank, and tissue enrichment analyses.
We have an exciting opportunity for a Postdoctoral Fellow to join Vento-Tormo Lab in our Cellular Genetics Programme for a 3 year contract. As part of Open Targets you will be working with other academic and industrial partners to develop immune cell screening platforms in order to target a large number of genes. We will use established CRISPR/Cas9 technology, but also develop new strategies to screen and multimodally assess gene perturbations in in vitro-derived immune cells. With this comprehensive approach, we will gain insight into the effects that gene perturbations have on transcriptional effects and their role in gene regulatory networks in the setting of different immune cell populations. This will inform target prioritisation in drug development processes.